Pharmaceuticals, Biotechnology and Life Sciences
– Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory…
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia…
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a…
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides…
MIRAMAR, Fla., March 28, 2025 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage…
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used…
Company announcement no. 6-2528 March 2025 NTG Nordic Transport Group A/S – Annual General Meeting 2025 Today, at 14:00, NTG Nordic Transport…
Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development…
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage…
UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., March 28,…